Sharekhan has given Buy recommendation for Solara Active Pharma Sciences with a target price of Rs. 1730 in its research report issued on Apr 12, 2021

Sharekhan’s research report on Solara Active Pharma Sciences

The Board of Solara has approved the amalgamation of Aurore Life Sciences, Empyrean Life Sciences, and Hydra Active Pharma Sciences with Solara. The merger opens up substantial growth opportunities for Solara going ahead. The combined entity would be a pure play API company of scale, with a strong presence in regulated markets and emerging markets, having a broad product portfolio, robust operations infrastructure, and excellent R&D capabilities; and it would strengthen the CRAMS business of Solara with clear synergies to further accelerate growth.


We retain our Buy recommendation on the stock with a revised PT of Rs. 1,730.